Regulation of estrogen receptor α function in breast cancer

Critical Reviews in Oncogenesis

Volumn 8, Issue 1, 1997, Pages 29-46

  Ferguson, Anne T ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alternative splicing; Coactivators; Methylation; Mutation; Phosphorylation; Transcription

Indexed keywords

4 HYDROXYTAMOXIFEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT; GONADORELIN DERIVATIVE; HORMONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; RECEPTOR PROTEIN; RECEPTOR SUBUNIT; SERINE; TAMOXIFEN; TYROSINE;

ALPHA CHAIN; ALTERNATIVE RNA SPLICING; BREAST CANCER; BREAST EPITHELIUM; CANCER HORMONE THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; POINT MUTATION; PROTEIN PHOSPHORYLATION; RECEPTOR GENE; REVIEW;

EID: 0031407236     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i1.20     Document Type: Review

References (111)

1. Adler, S., M. L. Waterman, and M. G. Rosenfeld: Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell, 52:685-695 (1988).
2. Ali, S., D. Metzget, J.-M. Bornet, and P. Chambon: Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J., 12:1153-1160 (1993).
3. Altucci, L., R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, M. Truss, M. Beato, V. Sica, F. Bresciani, and A. Weisz: 17β-estradiol induces cyclin D1 gene transcription, p36D1-p34 cdk complex activation and p105 Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene, 12:2315-2324 (1996).
4. Alvarez, E., B. E. Elliot, A. N. Houghton, and R. S. Kerbel: Heritable high-frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2′-deoxycytidine or hydroxyurea: analysis and implications. Cancer Res., 40:277-280 (1988).
5. Antequera, F., J. Boyes, and A. Bird: High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell, 62:503-514 (1990).
6. Anzick, S. L., J. Kononen, R. L. Walker, D. O. Azorsa, M. M. Tanner, X. Y. Guan, G. Sauter, O. P. Kallionlemi, J. M. Trent, and P. S. Meltzer: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science, 277:965-968 (1997).
7. Arnold, S. F. and A. C. Notides: An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A., 92:7475-7479 (1995).
8. Arnold, S. F., M. Melamed, D. P. Vorojeikina, A. C. Notides, and S. Sasson: Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol. Endocrinol., 11:48-53 (1997).
9. Baniahmad, C., Z. Nawaz, A. Baniahmad, M. A. G. Gleeson, M.-J. Tsai, and B. W. O'Malley: Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol. Endocrinol., 9:34-43 (1995).
10. Bates, S. E., N. E. Davidson, E. M. Valverius, C. E. Freter, R. B. Dickson, J. P. Tam, J. E. Kudlow, M. E. Lippman, and D. S. Salomon: Expression of transforming growth factor a and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol., 2:543-555 (1988).
11. Beato, M., R. Candau, S. Chavez, C. Mows, and M. Truss: Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. J. Steroid Biochem. Mol. Biol., 56:47-59 (1996).
12. Beekman, J. M., G. F. Allan, S. Y. Tsai, M.-J.-Tsai, and B. W. O'Malley: Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol., 7:1266-1274 (1993).
13. Bird, A. P.: CpG-rich islands and the function of DNA methylation. Nature, 321:209-213 (1986).
14. Bunone, G., P.-A. Briand, R. J. Miksicek, and D. Picard: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J., 15:2174-2183 (1996).
15. Carmeci C., E. C. deConinck, T. Lawston, D. A. Block, and R. J. Weigel: Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology. Am. J. Pathology, 150:1563-1570 (1997).
16. Castles, C. G., S. A. W. Fuqua, D. M. Klotz, and S. M. Hill: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res., 53:5934-5939 (1993).
17. Chen, J. D. and R. M. Evans: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature, 377:454-457 (1995).
18. Comb, M. and H. M. Goodman: CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res., 18:3975-3982 (1990).
19. Courjal, F., M. Cuny, C. Rodriquez, G. Louason, P. Speiser, D. Katsaros, M. M. Tanner, R. Zeillinger, and C. Theillet: DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br. J. Cancer, 74:1984-1989 (1996).
20. Daffada, A. A. I., S. R. D. Johnston, I. E. Smith, S. Detre, N. King, and M. Dowsett: Exon5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res., 55:288-293 (1995).
21. Dean, D. M. and M. M. Sanders: Ten years after: reclassification of steroid-responsive genes. Mol. Endocrinol., 10:1489-1495 (1996).
22. deConinck, E. C., L. A. McPherson, and R. J. Weigel: Transcriptional regulation of estrogen receptor in breast carcinomas. Mol. Cell. Biol., 15:2191-2196 (1995).
23. Denton, R. R., N. J. Koszewski, and A. C. Notides: Estrogen receptor phosphorylation. J. Biol. Chem., 267:7263-7268 (1992).
24. Dubik, D. and R. P. C. Shiu: Transcriptional regulation of cmyc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J. Biol. Chem., 263:12705-12708 (1988).
25. Ferguson, A. T., R. G. Lapidus, S. B. Baylin, and N. E. Davidson: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res., 55:2279-2283 (1995).
26. Ferguson, A. T., P. M. Vertino, J. R. Spitzner, S. B. Baylin, M. T. Muller, and N. E. Davidson: Role of estrogen receptor gene demethylation and DNA methyltransferase-DNA adduct formation in 5-aza-2′-deoxycytidine-induced cytotoxicity in human breast cancer cells. J. Biol. Chem., 1997.
27. Ferguson, A. T., R. G. Lapidus, K. Butash, and N. E. Davidson: Roles of DNA methylation and histone acetylation in regulating ER and PR gene expression, submitted.
28. Fujii, H., C. Marsh, P. Cairns, D. Sidransky, and E. Gabrielson: Genetic divergence in clonal evolution of breast cancer. Cancer Res., 56:1493-1497 (1996).
29. Fuqua, S. A. W., S. D. Fitzgerald, G. C. Chamness, A. K. Tandon, D. P. McDonnell, Z. Nawaz, B. W. O'Malley, and W. L. McGuire: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res., 51:105-109 (1991).
30. Fuqua, S. A. W., S. D. Fitzgerald, D. C. Allred, R. M. Elledge, Z. Nawaz, D. P. McDonell, B. W. O'Malley, G. L. Greene, and W. L. McGuire: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res., 52:483-486 (1992).
31. Fuqua, S. A. W., G. C. Chamness, and W. L. McGuire: Estrogen receptor mutations in breast cancer. J. Cell. Biochem., 51:135-139 (1993).
32. Gabbara, S. and A. S. Bhagwat: The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem. J., 307:87-92 (1995).
33. Garcia, T., M. Sanchez, J. L. Cox, P. A. Shaw, J. B. Ross, S. Lehre, and B. Schachter: Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res., 17:8364 (1989).
34. Graham, M. L., N. L. Kreet, L. A. Miller, K. K. Leslie, D. F. Gordon, W. M. Wood, L. L. Wei, and K. B. Horwitz: T47Dco cells, genetically unstable and containing estrogen receptor mutations are a model for the progression of breast cancers to hormone resistance. Cancer Res., 50:6208-6217 (1990).
35. Hanstein, B., R. Eckner, J. DiRenzo, S. Halachmi, H. Liu, B. Searcy, R. Kurokawa, and M. Brown: p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.SA., 93:11540-11545 (1996).
36. Herman, J. G., F. Latif, W. Weng, M. I. Lerman, B. Zbar, S. Liu, D. Samid, D. S. Duan, J. R. Gnarra, W. M. Linehan, and S. B. Baylin: Silencing of the VHL-tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U.S.A., 91:9700-9704 (1994).
37. Herman, J. G., A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin: Inactivation of the CDKN2/p16MSTl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55:4525-4530 (1995).
38. Horlein, A. J., A. M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C. K. Glass, and M. G. Rosenfeld: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature, 377:397-404 (1995).
39. Horwitz, K. B., T. A. Jackson, D. L. Bain, J. K. Richer, G. S. Takimoto, and L. Tung: Nuclear receptor coactivators and corepressors. Mol. Endocrinol, 10:1167-1177 (1996).
40. Howell, A., D. J. DeFriend, J. F. Robertson, R. W. Blarney, L. Anderson, E. Anderson, F. A. Sutcliffe, and P. Walton: Pharmokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182, 780 in women with advanced breast cancer. Br. J. Cancer, 74:300-308 (1996).
41. Huang, Y. and S. Friedman: Inhibition of recA-mediated strand exchange by adducts of azacytosine-containing DNA and the EcoRII methylase. J. Biol. Chem., 266:17424-17429 (1991).
42. Ignar-Trowbridge, D. M., K. G. Nelson, M. C. Bidwell, S. W. Curtis, T. F. Washburn, J. A. McLachlan, and K. S. Korach: Coupling of dual signaling pathways: epidermal growth factor action involves estrogen receptor. Proc. Natl. Acad. Sci. U.S.A., 89:4658-4662 (1991).
43. Ignar-Trowbridge, D. M., C. T. Teng, K. A. Ross, M. G. Parker, K. S. Korach, and J. A. McLachlan: Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol., 7:992-998 (1993).
44. Ing, N. H., J. M. Beekman, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley: Members of the steroid hormone receptor superfamily interact with TFIIB. J. Biol. Chem., 267:17617-17623 (1992).
45. Jablonka, E., R. Goitein, M. Marcus, and H. Cedar: DNA hypomethylation causes an increase in DNase I sensitivity and an advance in the time of replication of the entire inactive X chromosome. Chromosoma, 93:152-156 (1985).
46. Jackson, T. A., J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol., 11:693-705 (1997).
47. Jakowlev, S. B., R. Breathnach, J. M. Teltsa, P. Masaikowski, and P. Chambon: Sequence of pS2 mRNA induced by estrogen in the human breast cancer cell line, MCF-7. Nucl. Acids Res., 12:2861-2878 (1984).
48. Jenster, G., T. E. Spencer, M. M. Burcin, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley: Steroid receptor induction of gene transcription: a two step model. Proc. Natl. Acad. Sci. U.S.A., 94:7879-7884 (1997).
49. Jiang, S. Y. and V. C. Jordan: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst., 84:580-591 (1992).
50. Joel, P. B., A. M. Traisch, and D. A. Lannigan: Estradiol and phorbal ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol. Endocrinol., 9:1041-1052 (1995).
51. Karnik, P. S., S. Kulkarni, X. P. Liu, G. T. Budd, and R. M. Bukowski: Estrogen receptor mutation in tamoxifenresistant cancer. Cancer Res., 54:349-353 (1994).
52. Kato, S., H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, and P. Chambon: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 270:1491-1494 (1995).
53. Katzenellenbogen, B. S., H. Fang, B. A. Ince, F. Pakdel, J. C. Reese, C. H. Wooge, and C. K. Wrenn: Estrogen receptors: ligand discrimination and antiestrogen action. Breast Cancer Res. Treat., 27:17-26 (1993).
54. Klein-Hitpass, L., S. Y. Tsai, G. L. Greene, J. H. Clark, M. J. Tsai, and B. W. O'Malley: Specific binding of estrogen receptor to the estrogen response element. Mol. Cell. Biol., 9:43-49 (1989).
55. Knight, W. A., III, R. B. Livingston, E. J. Gregory, and W. L. McGuire: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res., 37:4669-4671 (1977).
56. Koehorst, S. G. A., H. M. Jacobs, J. H. H. Thijssen, and M. A. Blankenstein: Wild-type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 45:227-233 (1993).
57. Kraus, W. L., E. M. McInerney, and B. S. Katzenellenbogen: Ligand-dependent, transcriptionally productive association of the amino- and carboxy-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. U.S.A., 92:12314-12318 (1995).
58. Kuiper, G. G. J. M., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A. Gustafsson: Cloning of a novel estrogen receptor in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A., 93:5925-5930 (1996).
59. Kumar, V., S. Green, G. Stack, M. Berrry, J. R. Jin, and P. Chambon: Functional domains of the human estrogen receptor. Cell, 51:941-951 (1987).
60. Lapidus, R. G., A. T. Ferguson, Y. L. Ottaviano, F. F. Parl, H. S. Smith, S. A. Weitzman, S. B. Baylin, J. P. Issa, and N. E. Davidson: Methylation of estrogen and progesterone receptor CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res., 2:805-810 (1996).
61. Lee, J. W., F. Ryan, J. C. Swaffield, S. A. Johnson, and D. D. Moore: Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature, 374:91-94 (1995).
62. LeDouarin, B., C. Zechel, J. M. Garnier, Y. Lutz, L. Tora, B. Pierrat, D. Heery, H. Gronemeyer, P. Chambon, and R. Losson: The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J., 14:2020-2033 (1995).
63. LeGoff, P., M. M. Montano, D. J. Schodin, and B. S. Katzenellenbogen: Phosphorylation of the human estrogen receptor. J. Biol. Chem., 269:4458-4466.
64. Li, E., C. Beard, and R. Jaenisch: Role of DNA methylation in genomic imprinting. Nature, 366:362-365 (1993).
65. Markopoulus, C., U. Berger, P. Wilson, J. Gazet, and R. C. Coombes: Oestrogen receptor content of normal breast cells and breast carcinoma throughout the menstrual cycle. Br. Med. J., 296:1349-1351 (1988).
66. McDonnell, D. P., E. Vegeto, and B. W. O'Malley: Identification of a negative regulatory function for steroid receptors. Proc. Natl. Acad. Sci. U.S.A., 89:10563-10567 (1992).
67. McGuire, W. L.: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol., 12:317-326 (1978).
68. McGuire, W. L., G. C. Chamness, and S. A. W. Fuqua: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol., 5:1571-1577 (1992).
69. McPherson, L. A., V. R. Baichwal, and R. J. Weigel: Identification of ERF-1 as a member of the AP2 transcription factor family. Proc. Natl. Acad. Sci. U.S.A., 94:4342-4347 (1997).
70. Migliaccio, A., M. DiDomenico, S. Green, A. deFalco, E. L. Kajtaniak, F. Blasi, P. Chambon, and F. Auricchio: Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol. Endocrinol., 3:1061-1069 (1989).
71. Miksicek, R. J., Y. Lei, and Y. Wang: Exon skipping gives rise to alternatively spliced forms of the ER in breast tumor cells. Br. Cancer Res. Treatment, 26:163-174 (1993).
72. Mohandas, T., R. S. Sparkes, and L. J. Shapiro: Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science, 211:393-396 (1981).
73. Montano, M. M., V. Muller, A. Trobaugh, and B. S. Katzenellenbogen: The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol., 9:814-825 (1995).
74. Muchardt, C. and M. Yaniv: A human homolog of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J., 12:4279-4290 (1993).
75. Murdoch, F. E., M. Fritsch, and J. Gorski: The estrogen receptor: mechanism of action and relationship to human breast cancer. ISI Atlas of Science: Pharmacology, 267-275 (1988).
76. Murphy, L. C. and H. Dotzlaw: Variant ER mRNA species detected in human breast cancer biopsy samples. Mol. Endocrinol., 3:687-693 (1989).
77. Nagy, L., H. Y. Kao, D. Chakravarti, R. J. Lin, C. A. Hassig, D. E. Ayer, S. L. Schreiber, and R. M. Evans: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase. Cell, 89:373- b 380 (1997).
78. Norris, J. D., D. Fan, S. A. Kerner, and D. P. McDonnell: Identification of a third autonomous activation domain within the human estrogen receptor. Mol. Endocrinol., 11:747-754 (1997).
79. Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell, 87:953-959 (1996).
80. Ohtani-Fujita N., T. Fujita, A. Aoike, N. E. Osifchin, P. D. Robbins, and T. Sakai: CpG methylation inactivates the promoter activity of the human retinoblastoma tumorsuppressor gene. Oncogene, 8:1063-1067 (1993).
81. Onate, S. O., S. Y. Tsai, M. J. Tsai, and B. W. O'Malley: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science, 270:1354-1356 (1995).
82. Ottaviano, Y. L., J. P. Issa, F. F. Pari, H. S. Smith, S. B. Baylin, and N. E. Davidson: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 54:2552-2555 (1994).
83. Pari, F. F., D. R. Cavener, and W. D. Dupont: Genomic DNA analysis of the estrogen receptor gene in breast cancer. Br. Cancer Res. Treat., 14:57-64 (1989).
84. Pinto, A., V. Attadia, A. Fusco, F. Ferrara, O. A. Spada, and P. P. DiFiore: 5-aza-2′-deoxycytidine induces terminal differentiation of leukemia blasts from patients with acute myeloid leukemias. Blood, 64:922-929 (1984).
85. Pinto, A. and V. Zagonel: 5-aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia, 7:51-60 (1993).
86. Read, L. D., C. E. Snider, J. S. Miller, G. L. Greene, and B. S. Katzenellenbogen: Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol. Endocrinol., 2:263-271 (1988).
87. Rhea, D. and M. G. Parker: Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res., 56:1556-1563 (1996).
88. Roodi, N., L. R. Bailey, W. Y. Kao, C. S. Verrier, C. J. Yee, W. D. Dupont, and F. F. Pari: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst., 87:446-451 (1995).
89. Sadovsky, Y., P. Webb, G. Lopez, J. D. Baxter, P. M. Fitzpatrick, E. Gizang-Ginsberg, V. Cavailles, M. G. Parker, and P. Kushner: Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol. Cell. Biol., 15:1554-1563 (1995).
90. Schodin, D. J., Y. Zhuang, D. J. Shapiro, and B. S. Katzenellenbogen: Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness. J. Biol. Chem., 270:31163-31171 (1995).
91. Scott, G. K., P. Kushner, J. L. Vigne, and C. C. Benz: Truncated forms of DNA binding estrogen receptors in human breast cancer. J. Clin. Invest., 88:700-706 (1991).
92. Sigurdsson, H., B. Baldetorp, A. Borg, M. Dalberg, M. Ferno, D. Killander and H. Olson: Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med., 322:1045-1053 (1990).
93. Smith, D. F. and D. O. Toft: Steroid receptors and their associated proteins. Mol. Endocrinol., 7:4-11 (1993).
94. Smith, C. L., S. A. Onate, M. J. Tsai, and B. W. O'Malley: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. U.S.A., 93:8884-8888 (1996).
95. Smith, C. L., Z. Nawaz, and B. W. O'Malley: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol., 11:657-666 (1997).
96. Tang, Z., I. Treilleux, and M. Brown: A transcriptional enhancer required for the differential expression of the human estrogen receptor. Mol. Cell. Biol., 17:1274-1280 (1997).
97. Tora, L., J. White, C. Brou, D. Tasset, N. Webster, E. Scheer, and P. Chambon: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell, 59:477-487 (1989).
98. II30 affect estrogen receptor-mediated transcriptional activation. Mol. Endocrinol., 11:1009-1019 (1997).
99. Wang, Y. and R. J. Miksicek: Identification of a dominant negative form of the human estrogen receptor. Mol. Endocrinol., 8:1707-1715 (1991).
100. Wang, T. T. Y. and J. M. Phang: Effects of estrogen on apoptosis pathways in human breast cancer cell 'line MCF-7. Cancer Res., 55:2487-2489 (1995).
101. Watts, C. K., M. L. Handel, R. J. B. King, and R. L. Sutherland: Estrogen receptor gene structure and function in breast cancer. J. Steroid Biochem. Mol. Biol., 41:3-9 (1992).
102. Weigel, R. J., D. L. Crooks, J. D. Iglehart, and E. C. deConinck: Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma. Cell Growth Diff., 6:707-711 (1995).
103. Weis, K. A., K. Ekena, J. A. Thomas, G. Lazennec, and B. S. Katzenellenbogen: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol., 10:1388-1398 (1996).
104. White, R., M. Sjoberg, E. Kalkhoven, and M. G. Parker: Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J., 16:1427-1435 (1997).
105. Williamson, J. A., J. M. Bosher, A. Skinner, D. Sheer, T. Williams, and H. C. Hurst: Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics, 35:262-264 (1996).
106. Wolf, D. M. and V. C. Jordan: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Br. Cancer Res. Treat., 31:129-138 (1994).
107. Yen, P. M. and W. W. Chin: Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol. Endocrinol., 8:1450-1454 (1994).
108. Yoshiura, K., Y. Kanai, A. Ochiai, Y. Shimoyama, T. Sugimura, and S. Hirohashi: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. U.S.A., 92:7416-7419 (1995).
109. Zajchowski, D. A., R. Sager, and L. Webster: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res., 53:5004-5011 (1993).
110. Zhang, Q., A. Borg, and S. A. Fuqua: An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res., 53:5882-5884 (1993).
111. Zhang, Q. X., A. Borg, D. M. Wolf, S. Osterreich, and S. A. W. Fuqua: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res., 57:1244-1249 (1997).